A. Stopeck

414 total citations
20 papers, 295 citations indexed

About

A. Stopeck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Stopeck has authored 20 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in A. Stopeck's work include Cancer Cells and Metastasis (6 papers), Bone health and treatments (5 papers) and Cancer Treatment and Pharmacology (4 papers). A. Stopeck is often cited by papers focused on Cancer Cells and Metastasis (6 papers), Bone health and treatments (5 papers) and Cancer Treatment and Pharmacology (4 papers). A. Stopeck collaborates with scholars based in United States, Switzerland and Canada. A. Stopeck's co-authors include Jeri Matera, Michael Craig Miller, W. Jeffrey Allard, C. Rao, Mark C. Connelly, Madeline Repollet, Shanu Modi, Alison L. Hannah, C. Hudis and Robert G. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

A. Stopeck

19 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Stopeck United States	9	242	90	80	68	56	20	295
Marie‐Therese Haider Germany	11	232 1.0×	86 1.0×	57 0.7×	150 2.2×	43 0.8×	16	332
C. P. Carden United Kingdom	6	213 0.9×	139 1.5×	140 1.8×	104 1.5×	23 0.4×	8	358
Elisabeth Trapp Germany	13	303 1.3×	252 2.8×	97 1.2×	133 2.0×	24 0.4×	25	417
Santino Minichillo Italy	9	160 0.7×	137 1.5×	120 1.5×	84 1.2×	35 0.6×	17	347
Nicolas Kiavué France	10	257 1.1×	179 2.0×	110 1.4×	110 1.6×	36 0.6×	13	363
M. Campone France	8	128 0.5×	44 0.5×	86 1.1×	79 1.2×	16 0.3×	21	217
Maria Cristina Figueroa Magalhães Brazil	6	153 0.6×	132 1.5×	70 0.9×	82 1.2×	54 1.0×	22	308
José Roberto Freitas Rossari Belgium	6	273 1.1×	157 1.7×	107 1.3×	68 1.0×	27 0.5×	8	329
Yuanxi Huang China	9	149 0.6×	145 1.6×	39 0.5×	180 2.6×	18 0.3×	29	341
Birgit Wackwitz Germany	5	246 1.0×	116 1.3×	91 1.1×	101 1.5×	78 1.4×	7	331

Countries citing papers authored by A. Stopeck

Since Specialization

Citations

This map shows the geographic impact of A. Stopeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Stopeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Stopeck more than expected).

Fields of papers citing papers by A. Stopeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Stopeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Stopeck. The network helps show where A. Stopeck may publish in the future.

Co-authorship network of co-authors of A. Stopeck

This figure shows the co-authorship network connecting the top 25 collaborators of A. Stopeck. A scholar is included among the top collaborators of A. Stopeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Stopeck. A. Stopeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Stopeck, A., et al.. (2020). Oxylipins Correlate with Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 29(3). 691–691.

2.

Miao, Jieling, A. Stopeck, Paul Thompson, et al.. (2019). Abstract P1-17-03: Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307). Cancer Research. 79(4_Supplement). P1–17. 1 indexed citations

3.

Chaudhry, Basit, L. Baer, Andrzej P. Kudelka, Joshua D. Cohen, & A. Stopeck. (2019). Abstract P1-11-22: Aromatase inhibitors are significantly better tolerated by early stage breast cancer patients 75 or older and with significantly lower early discontinuation rate. Cancer Research. 79(4_Supplement). P1–11. 1 indexed citations

4.

Stopeck, A., et al.. (2018). Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC). Cancer Research. 78(4_Supplement). OT1–1. 3 indexed citations

5.

Shagisultanova, Elena, A. Stopeck, Lajos Pusztai, et al.. (2018). Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer. Cancer Research. 78(4_Supplement). OT1–3. 1 indexed citations

6.

Stopeck, A., Allan Lipton, Miguel Martín, et al.. (2011). P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study.. Cancer Research. 71(24_Supplement). P3–16. 13 indexed citations

7.

Diel, Ingo, J.J. Body, A. Stopeck, et al.. (2011). 3051 POSTER Effect of Denosumab Treatment on Prevention of Hypercalcemia of Malignancy in Cancer Patients With Metastatic Bone Disease. European Journal of Cancer. 47. S237–S237. 5 indexed citations

8.

Stopeck, A., et al.. (2010). Abstract P6-14-09: Acute-Phase Reactions Following Treatment with Zoledronic Acid or Denosumab: Results from a Randomized, Controlled Phase 3 Study in Patients with Breast Cancer and Bone Metastases. Cancer Research. 70(24_Supplement). P6–14. 4 indexed citations

9.

Stopeck, A., Roger von Moos, David H. Henry, et al.. (2010). A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases.. Journal of Clinical Oncology. 28(15_suppl). 9015–9015. 4 indexed citations

10.

Stopeck, A., et al.. (2009). The effect of sulindac on growth differentiation factor 15 and 13,14-dihydro-15-keto prostaglandin A2 in nipple aspirate fluid. BMC Proceedings. 3(S5). 1 indexed citations

11.

Rugo, Hope S., Sandra Franco, P.N. Munster, et al.. (2008). A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1042–1042. 16 indexed citations

12.

Modi, Shanu, S. Sugarman, A. Stopeck, et al.. (2008). Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1027–1027. 50 indexed citations

13.

Modi, Shanu, A. Stopeck, Michael S. Gordon, et al.. (2006). Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). Journal of Clinical Oncology. 24(18_suppl). 501–501. 8 indexed citations

14.

Stopeck, A., William Bellamy, Joseph M. Unger, et al.. (2005). Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin’s lymphoma (NHL): Southwest Oncology Group Study S0108. Journal of Clinical Oncology. 23(16_suppl). 6592–6592. 30 indexed citations

15.

Stopeck, A., Massimo Cristofanilli, G. Thomas Budd, et al.. (2005). Circulating tumor cells - not serum tumor markers - predict survival in metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 9516–9516. 5 indexed citations

16.

Cristofanilli, Massimo, G. T. Budd, Matthew J. Ellis, et al.. (2005). Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis. Journal of Clinical Oncology. 23(16_suppl). 524–524. 8 indexed citations

17.

Budd, G. T., Massimo Cristofanilli, Matthew J. Ellis, et al.. (2005). Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 503–503. 10 indexed citations

18.

Allard, W. Jeffrey, Jeri Matera, Michael Craig Miller, et al.. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Journal of Clinical Oncology. 22(14_suppl). 9552–9552. 32 indexed citations

19.

Allard, W. Jeffrey, Jeri Matera, Michael Craig Miller, et al.. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Journal of Clinical Oncology. 22(14_suppl). 9552–9552. 101 indexed citations

20.

Hayes, Daniel F., G. T. Budd, A. Stopeck, et al.. (2004). Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria. Journal of Clinical Oncology. 22(14_suppl). 509–509. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact